Chemoradiation in bladder cancer;Chimioradiothérapie concomitante des carcinomes de la vessie

Bulletin du Cancer

Volumn 92, Issue 12, 2005, Pages 1073-1077

  Durdux, Catherine ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Bladder; Chemotherapy; Radiotherapy; Transitional cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CISPLATIN DERIVATIVE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; TAXANE DERIVATIVE; VINBLASTINE;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CYSTECTOMY; CYSTOSCOPY; FEBRILE NEUTROPENIA; HUMAN; METASTASIS; PROGNOSIS; PROSTATE CARCINOMA; REVIEW; SIDE EFFECT; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYSTECTOMY; HUMANS; PILOT PROJECTS; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 30544436536     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Cookson MS. The surgical management of muscle invasive bladder cancer: a contemporary review. Sem Radiat Oncol 2005; 15: 10-8.
2. Soloway MS, Lopez AE, Patel J, Lu Y. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer 1994; 73: 1926-31.
3. Stein JP, Liekovsky G, Cote R. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001; 19: 666-75.
4. Bassi P, Ferrante GD, Piazza N. Prognostic factors after radical cystectomy for bladder cancer: a retrospective study of homogeneous patient cohort. J Urol 1999; 161: 1494-7.
5. Lebret T, Herve JM. Étude de la survie après cystectomie pour cancer de la vessie: à propos de 504 cas. Prog Urol 2000; 10: 553-60.
6. Gschwend JE, Dahm P, Fair WR. Disease specific survival as endpoint of outcome for bladder cancer patients following radical cysrectomy. Eur Urol 2002; 41: 440-8.
7. Schoenberg MP, Walsh PC, Breazeale R. Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10 year follow-up. J Urol 1996; 155: 490-4.
8. Zerbib M, Thitouard D, Conquy S, Flam T, Debré B. Évolution des techniques chirurgicales et résultats des cystectomies à visée curative pour cancer de vessie: à propos de 106 patients. Cancer Radiother 1998; 2: 505-11.
9. Ponvert D, Giraud P, Gaboriaud G. La radiothérapie dans le traitement des tumeurs infiltrantes de vessie. Oncology 2002; 2: 340-7.
10. Shelley MD, Barber J, Wilt T, Mason MD. Cochrane Database Syst Rev 2002; 1: CD002079.
11. Deweerd JM, Colby MY, Segura JW. Invasive bladder carcinoma managed by irradiation and surgery. Urology 1982; 20: 471-5.
12. Van der Werf Messing B. Carcinoma of the urinary bladder T3NXMO treared by preoperative radiation followed by simple cystectomy. Int J Radiat Oncol Biol Phys 1982; 8: 1849-55.
13. Von-der-Maase H. Current and future perspectives in advanced bladder cancer: is there a new standard? Sem Oncol 2002; 167: 2058-62.
14. Von-der-Maase H, Hansen SW, Roberts JT, Dolioti L, Olivier T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexte, vinblastine, doxorubicine, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2002; 17: 3068-77.
15. Meluch AA, Greco FA, Burris HA, O'Rourkr TO, Ortega G, Steis RG, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothehal tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2001; 19: 3018-24.
16. Prout GR, Shipley Wu, Kaufman DS. A progress report of the results of multimodality therapy for muscle-invasive bladder cancer. Sem Urol 1990; 8: 201-4.
17. Vale C, Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003; 361: 1927-34.
18. Durdux C. Sels de platine et radiothérapie: vingt ans de pratique. Cancer Radiother 2004(suppl. 1): S88-S94.
19. Wooddruff MW, Murphy W, Hopson JM. Further observation on the use of combination 5-fluorouracile and supervoltage irradiation therapy in the treatment of advanced carcinome of bladder. J Urol 1963; 90: 747-58.
20. Stein JJ, Kaufman DS. Treatment of carcinoma of the bladder with special reference to use preoperative radiation therapy combined with 5fluorouracile. Am J Roentgenol 1968; 102: 519-29.
21. Sauer R, Dunst J, Altendorfhofman A. Radiotherapy with and without cisplatin in bladder cancer. Int J Radiat Oncol Biol Phys 1990; 19: 687-91.
22. Tester W, Porter A, Asbell S. Combined modality program with possible organ preservation for invasive bladder carcinoma. Results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993; 25: 783-90.
23. Chauvet B, FelixFaure C, Davin JL, Choquenet C, Alfonsi M, Reboul F. Résultats à long terme du traitement des cancers infiltrants de vessie inopérables par cisplatine et radiothérapie concomitants: facteurs prédictifs du contrôle local et de la survie. Cancer Radiother 1998; 2: S85-91.
24. Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20: 3061-71.
25. Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J. Improved control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 2901-7.
26. Shipley WU, Zietman AL, Kaufman DS, Coen JJ, Sandler HM. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates. The Massachusetts General Hospital and Radiation therapy Oncology Group Experiences. Sem Oncol 2004; 15: 36-41.
27. Dunst J, Rodel C, Zietman A, Schkrott KM, Sauer R, Shipley WU. Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. Sem Surg Oncol 2001; 20: 24-32.
28. Housset M, Buthaud X. Intérêt de la radiochimiothé rapie concomitante dans le traitement des tumeurs infiltrantes de vessie: à propos d'une série de 173 cas. Thèse de Doctorat en médecine, université René Descartes, Paris, 16 octobre 2002.
29. Kachnic L, Kaufman D, Heney N, Althausen A, Griffin P, Zietman A. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997; 15: 1022-9.
30. Sauer R, Dunst J, Alttendorf-Hofmann A. Radiotherapy with and without cisplatin in bladder cancer. Int J Radiat Oncol Biol Phys 1990; 19: 687-91.
31. Arias F, Dominguez MA, Martinez E, Llarramendi JJ, Miquelez S, Pascual I, et al. Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys 2000; 47: 373-8.
32. Wammack R, Wricke C, Hohenfellner R. Long-term results of ileocecal continent urinary diversion in patients treated with or without previous pelvic irradiation. J Urol 2002; 167: 2058-62.
33. Eapen L, Stewart D, Collins J, Peterson R. Effective bladder sparing therapy with intra-arterial cisplatin radiotherapy for localized bladder cancer. J Urol 2004; 172: 1276-80.
34. Miyanaga N, Akaza H, Okumura T, Sekido N, Kawai K. A bladder preservation regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer: a prospective study. Int J Urol 2000; 7: 41-8.
35. Granaha F, Ymada T, Ujita M, Irie T, Fukada Y, Fukada K. Intra-arterial low-dose cisplatin via an indwelling port and concurrent radiotherapy for invasive bladder cancer. J Vasc Interv Radiol 2001; 12: 379-84.
36. Housset M, Fitreman C, Dufour B. Quality of life after combined radiation and chemotherapy with organ sparing for invasive bladder cancer. Proc ASTRO 1998: A2120.
37. Zietman AL, Sacco D, Skowronski U, Gomery P, Kaufman DS, Talcott JA, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003; 170: 1772-6.
38. Rodel C, Grabenbauer GG, Rodel F, Birkenhake S, Kuhn R, Martus P, et al. Apoptosis, p53, bcl2 and Ki67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 2000; 46: 1213-21.
39. Pollack A, Wu CS, Cserniak B, Zagars GK, Benedict WF, McDonel TJ. Abnormal bcl2 and pRB expression are independant correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 1997; 3: 1823-9.
40. Varveris H, Delakas D, Anezinis P, Haldeopoulos D, Mazonakis M, Damilakis J, et al. Concurrent platinum and docetaxel chemotheray and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma: a preliminary report of tolerance and local control. Anticancer Res 1997; 17: 4771-80.
41. Caffo O, Fellin G, Graffer U, Valduga F, Bolner A, Luciani L, et al. Phase I of gemcitabine and radiotherapy plus cisplatin transurethral resection as conservative treatment for infiltrative bladder cancer. Int J Radiat Oncol Biol Phys 2003; 57: 1310-6.
42. McBrain AC, Logue JP. Radiation therapy for muscle-invasive bladder cancer: treatment planning and delivery in the 21st century. Semin Radiat Oncol 2005; 15: 42-8.
43. Budgell G, Mott J, Hounsell A. Clinical implementation of dynamic multileaf collimation for compensated bladder treatments. Radiother Oncol 2001; 59: 31-8.
44. Hagan MP, Winter KA, Kaufman DS, Wajman Z, Zietman AL, Tookel LM, et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 665-72.
45. Chrétien Y, Oudard S, Durdux C. Actualités dans les cancers de la vessie. Bull Cancer 2003; 90: 61-7.